DCTH has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DCTH is 29.38M, and currently, short sellers hold a 3.42% ratio of that float. The average trading volume of DCTH on May 23, 2025 was 473.46K shares.
DCTH) stock’s latest price update
The stock price of Delcath Systems Inc (NASDAQ: DCTH) has plunged by -6.32 when compared to previous closing price of 17.24, but the company has seen a 0.62% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-22 that QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access. 2025 Full Year Financial Guidance The Company’s financial outlook for fiscal year 2025 is as follows: Total CHEMOSAT and HEPZATO KIT revenu.
DCTH’s Market Performance
DCTH’s stock has risen by 0.62% in the past week, with a monthly rise of 35.03% and a quarterly rise of 8.53%. The volatility ratio for the week is 5.31% while the volatility levels for the last 30 days are 5.78% for Delcath Systems Inc The simple moving average for the past 20 days is 13.27% for DCTH’s stock, with a 36.94% simple moving average for the past 200 days.
Analysts’ Opinion of DCTH
Many brokerage firms have already submitted their reports for DCTH stocks, with Craig Hallum repeating the rating for DCTH by listing it as a “Buy.” The predicted price for DCTH in the upcoming period, according to Craig Hallum is $18 based on the research report published on June 28, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see DCTH reach a price target of $25. The rating they have provided for DCTH stocks is “Overweight” according to the report published on May 14th, 2024.
Canaccord Genuity gave a rating of “Buy” to DCTH, setting the target price at $17 in the report published on July 26th of the previous year.
DCTH Trading at 23.39% from the 50-Day Moving Average
After a stumble in the market that brought DCTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.41% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 5.31%, as shares surge +33.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.27% upper at present.
During the last 5 trading sessions, DCTH rose by +0.62%, which changed the moving average for the period of 200-days by +94.11% in comparison to the 20-day moving average, which settled at $14.26. In addition, Delcath Systems Inc saw 34.14% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for DCTH
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.88 for the gross margin
The net margin for Delcath Systems Inc stands at -0.27. The total capital return value is set at -0.02. Equity return is now at value -29.95, with -23.02 for asset returns.
Based on Delcath Systems Inc (DCTH), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -6.79. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.74.
Currently, EBITDA for the company is -12.18 million with net debt to EBITDA at 3.33. When we switch over and look at the enterprise to sales, we see a ratio of 10.55. The receivables turnover for the company is 3.63for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.95.
Conclusion
To put it simply, Delcath Systems Inc (DCTH) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
